The addition of Pertuzumab to traditional Trastuzumab may inhibit the development of invasive breast cancer

A phase III clinical trial in a large sample of women with HER2-positive breast cancer suggests that post surgery patients who add a second HER2 targeted medicine, Pertuzumab, to standard of care, Tratuzumab, may show some modest benefits.

Patients who were given a second drug had a 19% lower chance of developing invasive breast cancer.

Read more from the original article on ASCO

PrecisionPlan for Oncology Professionals

Build Actionable, Patient-Specific Cancer Treatment Plans

Integrate or embed our cognitive computing platform into your health system or cancer center EMR to make optimal, personalized, and patient-centered decisions.

Our codified clinical knowledge allows for expert-to-expert consultations and actionable patient-specific pathways built in seconds. 

PrecisionPlan™ is a comprehensive and continuum-based platform that outlines in detail the most appropriate clinical guidance in chemotherapy, immunotherapy, genomic-guided targeted therapy, anti-hormonal therapy, radiation therapy, surgery, supportive care, palliative care and follow up/survivorship that is unique to each patient.

Topics: